Combination of these inflammatory markers into a CRP/Alb ratio had been demonstrated as a prognostic indicator in several kinds of cancers, such as colorectal (Ishizuka et al., 2016; Shibutani et al., 2016), gastric (Saito et al., 2018), esophageal (Wei et al., 2015), hepatocellular (Kinoshita et al., 2015), and pancreatic (Haruki et al., 2016; Liu et al., 2017). This evidence concerns the gene ALB and cancer.